Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05937906 |
| Title | Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %. (IMMUNOMEK) |
| Acronym | IMMUNOMEK |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | Yes |
| Sponsors | Centre Georges Francois Leclerc |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | FRA |
CKB BOOST